Drugs / QHRD107
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06532058 | Aug 2023 → Feb 2025 overdue | acute myeloid leukemia | Changzhou Qianhong Bio-pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QHRD107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532058 ↗ |
| Route | Oral | “QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）” NCT06532058 ↗ |